AMGN Amgen (AMGN) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0000318154
Congress · 2Form 144 · 4
Insider buyers, 180 days
0
Funds added, last quarter
1,463
13F, latest reported quarter
Conversions, 180 days
5
Codes C/M, not in net · $1.4M priced
What the filings say about AMGN
Insiders, 180 days
-$4.5M net sold
3 sellers · 0% of sales under a 10b5-1 plan
Congress, 1 year
2 bought · 2 sold
Latest: purchase, 2026-09-22
Planned sales (Form 144), 90 days
$4.1M
4 notices
Amgen insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, AMGEN INC insiders sold a net $4.5M of stock across 35 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Aug 11, 2026.
- The trade is 19.6% of the 6,404 shares held after it.
- 2 other insiders sold within 30 days.
- 1,463 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Business Development Khosla Rachna sold about $521.4K of AMGN on Aug 13, 2026; 2 other insiders sold within 30 days and 1,463 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Nov 12, 2025.
- The trade is 31.2% of the 6,404 shares held after it.
- 2 other insiders sold within 30 days.
- 1,463 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Business Development Khosla Rachna sold about $825.1K of AMGN on Aug 11, 2026; 2 other insiders sold within 30 days and 1,463 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on May 4, 2026.
- The trade is 26.8% of the 7,340 shares held after it.
- 2 other insiders sold within 30 days.
- 1,463 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP & CCO Grygiel Nancy A. sold about $792.3K of AMGN on Aug 6, 2026; 2 other insiders sold within 30 days and 1,463 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on May 4, 2026.
- The trade is 13.6% of the 7,340 shares held after it.
- 2 other insiders sold within 30 days.
- 1,463 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP & CCO Grygiel Nancy A. sold about $402.2K of AMGN on Aug 6, 2026; 2 other insiders sold within 30 days and 1,463 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Feb 19, 2025.
- The trade is 16.6% of the 12,462 shares held after it.
- 2 other insiders sold within 30 days.
- 1,463 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Human Resources Miller Derek sold about $832.9K of AMGN on Aug 6, 2026; 2 other insiders sold within 30 days and 1,463 funds added in the latest 13F quarter.35 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$4.5M over 180 days
-$4.1M over 90 days
below 78% of Pharma & Biotech
Congress
2 members bought in the last year
more than 76% of Pharma & Biotech
Funds
1,463 funds bought in last quarter
more than 99% of Pharma & Biotech
Revenue
+10.0% year over year
more than 59% of Pharma & Biotech
Margin
21.0% net margin
more than 87% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
2.5% of the float short (float per yahoo 2026-10-27) · 5.0 days to cover · settled 2026-10-15
below 62% of Pharma & Biotech
The situation: each line is one rule over one dataset
1 clinical trial was terminated, suspended or withdrawn in the last 90 days.
What changed in the last 30 days
Oct 1Rep. David J. Taylor sold $1.0K to $15K, disclosed 9 days after the trade
Why it matters
House members report a bracket, not an exact amount, and have 45 days to do it; the trade is weeks old when it becomes public.
Watch AMGN
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+56.3%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns AMGN: institutional holders (13F)
13F holdings, latest reported quarter
49,362,016 sh
$17.9B
35,250,101 sh
$12.8B
30,560,537 sh
$11.1B
29,075,329 sh
$10.5B
16,320,446 sh
$5.9B
Congress trades in AMGN
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Bought 2026-09-22 · disclosed 9 days later
$1,001 - $15,000
Sold 2026-08-26 · disclosed 10 days later
$1,001 - $15,000
Bought 2026-06-05 · disclosed 7 days later
$1,001 - $15,000
Sold 2026-04-17 · disclosed 21 days later
$15,001 - $50,000
Bought 2026-03-24 · disclosed 28 days later
$15,001 - $50,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
AMGN planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Khosla Rachna
Filed 2026-08-13
$516.8K
Khosla Rachna
Filed 2026-08-11
$828.4K
Derek Miller
Filed 2026-08-06
$1.6M
Grygiel Nancy A.
Filed 2026-08-06
$1.2M
AMGN mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
VanEck Biotech ETF
$60.3M position · as of 2026-06-30
15.2%
iShares Biotechnology ETF
$711.4M position · as of 2026-06-30
7.8%
Hennessy Total Return Fund
$3.8M position · as of 2026-07-31
7.5%
Invesco Nasdaq Biotechnology ETF
$4.8M position · as of 2026-05-31
7.1%
Select Biotechnology Portfolio
$343.9M position · as of 2026-05-31
6.5%
FT Vest DJIA Dogs 10 Target Income ETF
$5.1M position · as of 2026-07-31
5.7%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
417 registered trials, 101 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
141
Phase 1
24 active
67
Phase 2
13 active
119
Phase 3
50 active
35
Phase 4
7 active
2
Early Phase 1
0 active
37
Not applicable
3 active
16
Multi-phase
4 active
What changed recently
Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects W
2026-10-20 · Completed → Terminated · Sponsor decision
Phase 1
A Trial of Inebilizumab in Participants With Autoimmune Hepatitis
2026-10-17 · Not Yet Recruiting → Recruiting
Phase 3
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Su
2026-10-07 · Completion moved 2029-05-10 → 2029-08-10
Phase 2
Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity
2026-10-07 · Active Not Recruiting → Completed
Phase 1
Comparing the Extent to Which Romosozumab (AMG 785) is Made Available in the Body When A
2026-10-06 · Not Yet Recruiting → Recruiting
Phase 1
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor
2026-10-06 · Completion moved 2028-12-05 → 2031-03-06
PHASE1,PHASE2
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Government contracts
Award ceilings over the contract's life, subsidiaries included.
Not annual revenue (USASpending.gov).
Department Of Health And Human Services
TREATMENT FOR USE IN A MASS CASUALTY EVENT WHERE THROMBOCYTOPENIA OR PLATELET LOSS IS A MAJOR CONCER · 2022-09-30
$839.9M
Federal awards ≥ $25M in the last 90 days, matched via the SAM.gov parent registry
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Amgen Inc. Political Action Committee
Cycle 2026 · $1,299K spent
$1.1M
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · Mr. Bradway
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$24.7M
$49.4M
$8.5M
+67%
+92%
2024
$24.4M
$12.7M
$9.8M
+29%
+50%
2023
$22.6M
$29.1M
$7.7M
+38%
+38%
2022
$21.4M
$41.7M
$7.2M
+21%
+36%
2021
$21.7M
$17.0M
$7.4M
+1%
+23%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $4.5M sold by insiders over 180 days, 1,463 funds added last quarter, 2 House member(s) bought in 12 months, disclosed weeks after the trade, $4.1M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
AMGN financials
Revenue growth
+10.0%
XBRL, annual
Net margin
21.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$38.1B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM AMGN
| FY Dec 2025 | $36.8B |
| FY Dec 2024 | $33.4B |
| FY Dec 2023 | $28.2B |
| FY Dec 2022 | $26.3B |
| FY Dec 2021 | $26.0B |
| Jun 2026 | $10.1B |
| Mar 2026 | $8.6B |
| Dec 2025 | $9.9B |
| Sep 2025 | $9.6B |
| Jun 2025 | $9.2B |
| Mar 2025 | $8.1B |
| Dec 2024 | $9.1B |
| Sep 2024 | $8.5B |
At each fiscal year end
Single quarter
Net margin, TTM
+23.0%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM AMGN
| FY Dec 2025 | +21.0% |
| FY Dec 2024 | +12.2% |
| FY Dec 2023 | +23.8% |
| FY Dec 2022 | +24.9% |
| FY Dec 2021 | +22.7% |
| Jun 2026 | +23.6% |
| Mar 2026 | +21.1% |
| Dec 2025 | +13.5% |
| Sep 2025 | +33.7% |
| Jun 2025 | +15.6% |
| Mar 2025 | +21.2% |
| Dec 2024 | +6.9% |
| Sep 2024 | +33.3% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$10.2B
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM AMGN
| FY Dec 2025 | $8.1B |
| FY Dec 2024 | $10.4B |
| FY Dec 2023 | $7.4B |
| FY Dec 2022 | $8.8B |
| FY Dec 2021 | $8.4B |
| Jun 2026 | $3.5B |
| Mar 2026 | $1.5B |
| Dec 2025 | $961.0M |
| Sep 2025 | $4.2B |
| Jun 2025 | $1.9B |
| Mar 2025 | $980.0M |
| Dec 2024 | $4.4B |
| Sep 2024 | $3.3B |
At each fiscal year end
Single quarter
Debt to equity
4.90x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity AMGN
| FY Dec 2025 | 6.31x |
| FY Dec 2024 | 10.23x |
| FY Dec 2023 | 10.37x |
| FY Dec 2022 | 10.64x |
| FY Dec 2021 | 4.97x |
| Jun 2026 | 4.90x |
| Mar 2026 | 6.24x |
| Dec 2025 | 6.31x |
| Sep 2025 | 5.67x |
| Jun 2025 | 7.57x |
| Mar 2025 | 9.24x |
| Dec 2024 | 10.23x |
| Sep 2024 | 8.02x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.22x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt AMGN
| FY Dec 2025 | 0.18x |
| FY Dec 2024 | 0.19x |
| FY Dec 2023 | 0.13x |
| FY Dec 2022 | 0.25x |
| FY Dec 2021 | 0.28x |
| Jun 2026 | 0.22x |
| Mar 2026 | 0.19x |
| Dec 2025 | 0.18x |
| Sep 2025 | 0.24x |
| Jun 2025 | 0.21x |
| Mar 2025 | 0.21x |
| Dec 2024 | 0.19x |
| Sep 2024 | 0.12x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+91.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity AMGN
| FY Dec 2025 | +106.1% |
| FY Dec 2024 | +67.6% |
| FY Dec 2023 | +135.8% |
| FY Dec 2022 | +126.5% |
| FY Dec 2021 | +73.2% |
| Jun 2026 | +91.5% |
| Mar 2026 | +101.3% |
| Dec 2025 | +106.1% |
| Sep 2025 | +81.7% |
| Jun 2025 | +99.1% |
| Mar 2025 | +105.7% |
| Dec 2024 | +67.6% |
| Sep 2024 | +55.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+9.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets AMGN
| FY Dec 2025 | +8.5% |
| FY Dec 2024 | +4.3% |
| FY Dec 2023 | +8.3% |
| FY Dec 2022 | +10.4% |
| FY Dec 2021 | +9.5% |
| Jun 2026 | +9.5% |
| Mar 2026 | +8.6% |
| Dec 2025 | +8.5% |
| Sep 2025 | +7.7% |
| Jun 2025 | +7.4% |
| Mar 2025 | +6.5% |
| Dec 2024 | +4.3% |
| Sep 2024 | +4.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+17.4%
operating income after a 15.0% effective tax rate, over long-term 2026-06-30 plus current 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital AMGN
| FY Dec 2025 | +15.2% |
| FY Dec 2024 | +11.8% |
| FY Dec 2023 | +11.2% |
| FY Dec 2022 | +23.5% |
| FY Dec 2021 | +19.6% |
| Jun 2026 | +17.4% |
| Mar 2026 | +16.6% |
| Dec 2025 | +15.2% |
| Sep 2025 | +13.7% |
| Jun 2025 | +13.5% |
| Mar 2025 | +12.4% |
| Dec 2024 | +11.8% |
| Sep 2024 | +12.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+16.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed AMGN
| FY Dec 2025 | +13.6% |
| FY Dec 2024 | +9.8% |
| FY Dec 2023 | +12.3% |
| FY Dec 2022 | +19.4% |
| FY Dec 2021 | +15.2% |
| Jun 2026 | +16.6% |
| Mar 2026 | +15.8% |
| Dec 2025 | +13.6% |
| Sep 2025 | +12.5% |
| Jun 2025 | +12.0% |
| Mar 2025 | +10.7% |
| Dec 2024 | +9.8% |
| Sep 2024 | +8.6% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
27.82x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing AMGN
| FY Dec 2025 | 22.99x |
| FY Dec 2024 | 34.52x |
| FY Dec 2023 | 23.04x |
| FY Dec 2022 | 21.69x |
| FY Dec 2021 | 21.84x |
| Jun 2026 | 22.49x |
| Mar 2026 | 24.47x |
| Dec 2025 | 22.99x |
| Sep 2025 | 21.81x |
| Jun 2025 | 22.83x |
| Mar 2025 | 28.43x |
| Dec 2024 | 34.52x |
| Sep 2024 | 41.20x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$285.5B
market value at close 2026-10-27 on 2026-07-30 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value AMGN
| FY Dec 2025 | $221.7B |
| FY Dec 2024 | $188.2B |
| FY Dec 2023 | $207.8B |
| FY Dec 2022 | $171.5B |
| FY Dec 2021 | $152.0B |
| Jun 2026 | $238.8B |
| Mar 2026 | $235.0B |
| Dec 2025 | $221.7B |
| Sep 2025 | $197.1B |
| Jun 2025 | $198.3B |
| Mar 2025 | $215.9B |
| Dec 2024 | $188.2B |
| Sep 2024 | $224.5B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+4.2%
TTM free cash flow over market value at close 2026-10-27
FCF yield AMGN
| FY Dec 2025 | +4.6% |
| FY Dec 2024 | +7.4% |
| FY Dec 2023 | +4.8% |
| FY Dec 2022 | +6.3% |
| FY Dec 2021 | +6.6% |
| Jun 2026 | +5.2% |
| Mar 2026 | +4.5% |
| Dec 2025 | +4.6% |
| Sep 2025 | +7.6% |
| Jun 2025 | +7.1% |
| Mar 2025 | +6.5% |
| Dec 2024 | +7.4% |
| Sep 2024 | +3.6% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.88x
P/E over trailing EPS growth of 32%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing AMGN
| FY Dec 2025 | 0.26x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 7.15x |
| FY Dec 2022 | 1.23x |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.71x |
| Mar 2026 | 0.78x |
| Dec 2025 | 0.26x |
| Sep 2025 | 0.33x |
| Jun 2025 | 0.21x |
| Mar 2025 | 0.50x |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $36.8B | $33.4B | $28.2B | $26.3B |
| Operating income | $9.1B | $7.3B | $7.9B | $9.6B |
| Net income | $7.7B | $4.1B | $6.7B | $6.6B |
| EPS (diluted) | 14.23 | 7.56 | 12.49 | 12.11 |
| Operating cash flow | $10.0B | $11.5B | $8.5B | $9.7B |
| Cash | $9.1B | $12.0B | $10.9B | $7.6B |
| Long-term debt | $50.0B | $56.5B | $63.2B | $37.4B |
| Buybacks | $0 | $200.0M | $0 | $6.4B |
| Dividends paid | $5.1B | $4.8B | $4.6B | $4.2B |
SEC XBRL, fiscal years, as known on 2026-10-28
AMGN Stock Sonar score 6/7 axes
Find similar shapesCompareAMGN ranks highest on profitability (82nd percentile) and institutional and government (77th), and lowest on insider conviction (10th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
AMGN filings, in plain words
Are Amgen insiders buying or selling AMGN?
In the 180 days to 2026-10-28, Amgen insiders were net sellers, a net $4.5M across purchases and sales reported on Form 4, by 3 sellers.
Have members of Congress traded AMGN?
Yes. In the year to 2026-10-28, 2 House members disclosed buying AMGN and 2 House members disclosed selling it; the latest on record is a purchase by David J. Taylor dated 2026-09-22.
Are there planned insider sales of AMGN?
Yes. 4 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $4.1M of stock; the latest, by Khosla Rachna, was filed 2026-08-13.
Read the full summary
In the 180 days to 2026-10-28, Amgen insiders were net sellers of AMGN, a net $4.5M across purchases and sales reported on Form 4 by 3 sellers. None of the 7 insider sales was flagged as made under a Rule 10b5-1 plan. In the year to 2026-10-28, 2 members of Congress disclosed buying AMGN and 2 members disclosed selling it; the latest on record is a purchase by David J. Taylor dated 2026-09-22. Insiders filed 4 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $4.1M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
